• Issue
    Volume 51, Issue 9
    September 2021


Free Access

Issue Information

  • Pages: 1097-1099
  • First Published: 02 September 2021



Asthma and Rhinitis

Open Access

Efficacy of inhaled salbutamol with and without prednisolone for first acute rhinovirus-induced wheezing episode

  • Pages: 1121-1132
  • First Published: 01 June 2021
Description unavailable

In young, hospitalized children with first episode of rhinovirus-induced wheezing, high-dose salbutamol may interact with oral prednisolone. However, further trials are warranted.

The effects of increasing fruit and vegetable intake in children with asthma: A randomized controlled trial

  • Pages: 1144-1156
  • First Published: 01 July 2021
Description unavailable

In a 6-month RCT in asthmatic children, a high fruit and vegetable (F&V) diet more than doubled fruit and vegetable intake and increased plasma carotenoids, compared to the low F&V control group. The high F&V diet did not affect asthma exacerbations; however, changes in gut microbiome and improvements in lung function were observed. In the low F&V group, changes in gut microbiome, increased plasma CRP, increased HDAC activity and decreased GPR41 gene expression in PBMCs were observed.

Asthma and Rhinitis

ADRB2 haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis

  • Pages: 1157-1171
  • First Published: 15 June 2021
Description unavailable

Asthmatic children and young adults treated with inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) were more prone to asthma exacerbations if they were carriers of ADRB2 haplotype (Arg16Gln27) compared to non-carriers. The ADRB2 Arg16 haplotype, presumably mainly driven by the Arg16, increased the risk of asthma exacerbations in patients treated with ICS plus LABA. This finding could be beneficial in ADRB2 genotype-guided asthma treatment and might improve patient outcomes.


Open Access

Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: A double-blind placebo-controlled trial

  • Pages: 1172-1184
  • First Published: 21 July 2021
Description unavailable

Seventy-five severe asthma patients were included (38 OM-85; 37 placebo). While intention to treat (ITT) analysis revealed no difference in exacerbation frequencies between the groups after 18 months, per protocol analysis in patients with type 2 inflammation (PPT2) showed a non-significant decrease. Nasopharyngeal swabs detected a virus less frequently in the OM-85 group during respiratory tract infections. Immune-modulatory effects were seen in several plasma cytokines. To conclude, OM-85 might be an effective add-on therapy in severe asthma patients with type 2 inflammation.


Atopic dermatitis trajectories to age 8 years in the GUSTO cohort

  • Pages: 1195-1206
  • First Published: 26 July 2021
Description unavailable

Three AD trajectories—early transient, early persistent and late persistent were generated from the unsupervised machine learning approach. Early transient AD was associated with non-modifiable risk factors (male gender and family history of atopy) and increased wheezing while, persistent AD was associated with maternal antibiotic use, breastfeeding and increased food sensitization. Late persistent AD was the strongest phenotype associated with allergic disorders.

Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

  • Pages: 1207-1217
  • First Published: 30 June 2021
Description unavailable

  • Adults with hospital-diagnosed atopic dermatitis, asthma or both conditions have increased risk of death.
  • Adults with concomitant atopic dermatitis and asthma have increased risk of death compared to subjects with asthma alone.
  • Hospital admissions and emergency room visits for asthma were significant predictors of death for subjects with atopic dermatitis and asthma.